Table 1.
Comparisons of clinicopathological parameters among MUC, MUMPC, IMPC, and IDMPC
| Parameter | MUC (n = 19) | MUMPC (n = 17) | IMPC (n = 15) | IDMPC (n = 13) | p-valuea | |
|---|---|---|---|---|---|---|
| Age, mean (yr) | 52.7 ± 14.0 | 53.9 ± 11.8 | 45.9 ± 11.7 | 54.3 ± 12.6 | .22b | |
| NG | Low | 6 (31.6) | 1 (5.9) | 0 | 0 | < .01 |
| Intermediate | 11 (57.9) | 14 (82.4) | 4 (26.7) | 4 (30.8) | ||
| High | 2 (10.5) | 2 (11.8) | 11 (73.3) | 9 (69.2) | ||
| Mitosis | Low | 16 (84.2) | 13 (76.5) | 2 (13.3) | 2 (15.4) | < .01 |
| Intermediate | 1 (5.3) | 4 (23.5) | 3 (20.0) | 3 (23.1) | ||
| High | 2 (10.5) | 0 | 10 (66.7) | 8 (61.5) | ||
| ER | Negative | 0 | 0 | 5 (33.3) | 4 (30.8) | .04 |
| Positive | 19 (100) | 17 (100) | 10 (66.7) | 9 (69.2) | ||
| PR | Negative | 1 (5.3) | 1 (5.9) | 7 (46.7) | 5 (38.5) | .04 |
| Positive | 18 (94.7) | 16 (94.1) | 8 (53.3) | 8 (61.5) | ||
| HER2 | Negative | 18 (94.7) | 16 (94.1) | 9 (60.0) | 8 (61.5) | .01 |
| Positive | 1 (5.3) | 1 (5.9) | 6 (40.0) | 5 (38.5) | ||
| Ki-67 | Low | 11 (57.9) | 7 (41.2) | 1 (6.7) | 1 (7.7) | < .01 |
| High | 8 (42.1) | 10 (58.8) | 14 (93.3) | 12 (92.3) | ||
| MS | LA | 11 (57.9) | 6 (35.3) | 1 (6.7) | 1 (7.7) | < .01 |
| LB | 8 (42.1) | 11 (64.7) | 9 (60.0) | 8 (61.5) | ||
| HER2 | 0 | 0 | 2 (13.3) | 2 (15.4) | ||
| Basal-like | 0 | 0 | 3 (20.0) | 2 (15.4) | ||
| T-stage | 1 | 11 (57.9) | 6 (35.3) | 6 (40.0) | 4 (30.8) | .62 |
| 2 | 7 (36.8) | 7 (41.2) | 6 (40.0) | 7 (53.8) | ||
| 3 | 1 (5.3) | 4 (23.5) | 3 (20.0) | 2 (15.4) | ||
| LNM | Absence | 17 (89.5) | 13 (76.5) | 3 (20.0) | 4 (30.8) | < .01 |
| Presence | 2 (10.5) | 4 (23.5) | 12 (80.0) | 9 (69.2) |
Values are presented as number (%).
MUC, mucinous carcinoma without micropapillary feature; MUMPC, mucinous carcinoma with micropapillary feature; IMPC, invasive micropapillary carcinoma; IDMPC, mixed invasive ductal and micropapillary carcinoma; NG, nuclear grade; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; MS, molecular subtype; LA, luminal A; LB, luminal B; LNM, lymph node metastasis.
a
Chi-square test;
b
ANOVA test.